István Bitter1, Anna Angyalosi, Pál Czobor. 1. Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary. bitter.istvan@med.semmelweis-univ.hu
Abstract
PURPOSE OF REVIEW: This article reviews recent advances in the pharmacological treatment of adult attention deficit hyperactivity disorder (ADHD), focusing on the literature of the last 18 months. RECENT FINDINGS: Recent works highlight the growing number of treatment options and focus on the effects of pharmacological treatment in special areas of adult ADHD including emotional dysregulation, social functioning or driving performance. Significant clinical improvement was demonstrated in special subgroups, for example, in substance dependent or prison populations with adult ADHD. In our earlier meta-analysis, we estimated the effect size for the pharmacotherapy of adult ADHD in short-term placebo-controlled studies to be in the medium-to-high range (Cohen-d = 0.65). We now replicate these results with the help of most recent studies: stimulants had greater efficacy than nonstimulants. SUMMARY: Recent studies are consistent with prior reports and indicated that pharmacological treatment of adult ADHD is effective in improving symptoms and other domains, such as social dysfunction, functional impairment and executive functions. Furthermore, we calculated effect sizes from the most recent studies and they are almost identical with prior estimates, and in terms of Cohen-d typically indicate medium-to-high effect sizes for the pharmacotherapy of adult ADHD.
PURPOSE OF REVIEW: This article reviews recent advances in the pharmacological treatment of adult attention deficit hyperactivity disorder (ADHD), focusing on the literature of the last 18 months. RECENT FINDINGS: Recent works highlight the growing number of treatment options and focus on the effects of pharmacological treatment in special areas of adult ADHD including emotional dysregulation, social functioning or driving performance. Significant clinical improvement was demonstrated in special subgroups, for example, in substance dependent or prison populations with adult ADHD. In our earlier meta-analysis, we estimated the effect size for the pharmacotherapy of adult ADHD in short-term placebo-controlled studies to be in the medium-to-high range (Cohen-d = 0.65). We now replicate these results with the help of most recent studies: stimulants had greater efficacy than nonstimulants. SUMMARY: Recent studies are consistent with prior reports and indicated that pharmacological treatment of adult ADHD is effective in improving symptoms and other domains, such as social dysfunction, functional impairment and executive functions. Furthermore, we calculated effect sizes from the most recent studies and they are almost identical with prior estimates, and in terms of Cohen-d typically indicate medium-to-high effect sizes for the pharmacotherapy of adult ADHD.
Authors: Marc A Mergy; Raajaram Gowrishankar; Gwynne L Davis; Tammy N Jessen; Jane Wright; Gregg D Stanwood; Maureen K Hahn; Randy D Blakely Journal: Neurochem Int Date: 2013-12-08 Impact factor: 3.921
Authors: Christopher Hautmann; Manfred Döpfner; Josepha Katzmann; Stephanie Schürmann; Tanja Wolff Metternich-Kaizman; Charlotte Jaite; Viola Kappel; Julia Geissler; Andreas Warnke; Christian Jacob; Klaus Hennighausen; Barbara Haack-Dees; Katja Schneider-Momm; Alexandra Philipsen; Swantje Matthies; Michael Rösler; Wolfgang Retz; Alexander von Gontard; Esther Sobanski; Barbara Alm; Sarah Hohmann; Alexander Häge; Luise Poustka; Michael Colla; Laura Gentschow; Christine M Freitag; Katja Becker; Thomas Jans Journal: BMC Psychiatry Date: 2018-12-13 Impact factor: 3.630